In this study antibody isotype analysis revealed AMP-CpG formulated EBV vaccine generated a mixture of IgA, IgM, IgG1, IgG2a, IgG2b, and IgG3 gp350-specific antibody isotypes, suggesting the potential for immunization with AMP-CpG to promote enhanced immune control of primary infection and prevention of progression to symptomatic IM. Here, CD79A is linked to infection.